John F. Sullivan

1.6k total citations · 1 hit paper
14 papers, 955 citations indexed

About

John F. Sullivan is a scholar working on Infectious Diseases, Surgery and Virology. According to data from OpenAlex, John F. Sullivan has authored 14 papers receiving a total of 955 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Infectious Diseases, 4 papers in Surgery and 4 papers in Virology. Recurrent topics in John F. Sullivan's work include HIV Research and Treatment (4 papers), HIV/AIDS drug development and treatment (3 papers) and HIV/AIDS Research and Interventions (2 papers). John F. Sullivan is often cited by papers focused on HIV Research and Treatment (4 papers), HIV/AIDS drug development and treatment (3 papers) and HIV/AIDS Research and Interventions (2 papers). John F. Sullivan collaborates with scholars based in United States, United Kingdom and Australia. John F. Sullivan's co-authors include Elna van der Ryst, Nathan Clumeck, Bonaventura Clotet, Howard Mayer, James Goodrich, Anders Karlsson, Michael W. Dunne, Caroline E. Ridgway, Andrzej Horban and Steve Felstead and has published in prestigious journals such as New England Journal of Medicine, Radiology and The Journal of Infectious Diseases.

In The Last Decade

John F. Sullivan

14 papers receiving 915 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

2008 570 citations Roy M. Gulick, Jacob Lalezari et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John F. Sullivan United States	10	574	502	154	130	125	14	955
Claire Raskino United States	12	365 0.6×	307 0.6×	103 0.7×	117 0.9×	76 0.6×	19	713
Antonio Chirianni Italy	17	429 0.7×	553 1.1×	292 1.9×	95 0.7×	80 0.6×	70	1.1k
Vincenzo Spagnuolo Italy	17	521 0.9×	643 1.3×	185 1.2×	83 0.6×	33 0.3×	99	979
Miguel López-Dupla Spain	20	209 0.4×	262 0.5×	325 2.1×	38 0.3×	127 1.0×	59	904
Beverly Alston‐Smith United States	13	281 0.5×	421 0.8×	329 2.1×	133 1.0×	46 0.4×	23	1.0k
Piétro Scalfaro Switzerland	17	176 0.3×	233 0.5×	576 3.7×	98 0.8×	118 0.9×	35	1.4k
T. K. Sreepada Rao United States	15	209 0.4×	544 1.1×	241 1.6×	17 0.1×	62 0.5×	27	1.2k
Christoph Wyen Germany	22	604 1.1×	1.0k 2.0×	293 1.9×	22 0.2×	40 0.3×	70	1.7k
Hamid Hasson Italy	13	345 0.6×	468 0.9×	224 1.5×	17 0.1×	65 0.5×	69	792
Claudia Martorell United States	14	217 0.4×	467 0.9×	598 3.9×	25 0.2×	75 0.6×	28	1.3k

Countries citing papers authored by John F. Sullivan

Since Specialization

Citations

This map shows the geographic impact of John F. Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Sullivan more than expected).

Fields of papers citing papers by John F. Sullivan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Sullivan. The network helps show where John F. Sullivan may publish in the future.

Co-authorship network of co-authors of John F. Sullivan

This figure shows the co-authorship network connecting the top 25 collaborators of John F. Sullivan. A scholar is included among the top collaborators of John F. Sullivan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. Sullivan. John F. Sullivan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Schumann, Tina, Jörg König, Christian von Loeffelholz, et al.. (2021). Deletion of the diabetes candidate gene Slc16a13 in mice attenuates diet-induced ectopic lipid accumulation and insulin resistance. Communications Biology. 4(1). 826–826. 14 indexed citations

Simpson, Paul, Julie Mori, John F. Sullivan, et al.. (2021). V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens. Antiviral chemistry & chemotherapy. 29. 892421484–892421484. 2 indexed citations

Sullivan, John F., et al.. (2019). Preoperative Urine Culture Does Not Reliably Correlate with Intraoperative Stone Culture in Patients Undergoing Endoscopic or Percutaneous Management for Urolithiasis. Journal of the American College of Surgeons. 229(4). S320–S321. 1 indexed citations

Sullivan, John F., et al.. (2019). The transobturator sub-urethral sling: A safe and effective option for all degrees of post prostatectomy urinary incontinence. European Urology Supplements. 18(1). e1065–e1066. 4 indexed citations

Saag, Michael S., James Goodrich, Gerd Fätkenheuer, et al.. (2009). A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1. The Journal of Infectious Diseases. 199(11). 1638–1647. 108 indexed citations

Gulick, Roy M., Jacob Lalezari, James Goodrich, et al.. (2008). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. New England Journal of Medicine. 359(14). 1429–1441. 570 indexed citations breakdown →

Dyer, Wayne B., et al.. (2007). Drug Resistance and Viral Evolution in Plasma and Peripheral Blood Cells During Structured Treatment Interruption (STI) and Non-Interrupted HAART. Current HIV Research. 5(2). 235–250. 15 indexed citations

Corea, L, et al.. (1996). Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine*. Clinical Pharmacology & Therapeutics. 60(3). 341–346. 124 indexed citations

Gangadharam, P R, et al.. (1992). In vitro, in vivo, and intracellular chemotherapeutic activity of B746, a clofazimine analogue against Mycobacterium avium complex. Tubercle and Lung Disease. 73(4). 192–199. 10 indexed citations

10.

Lang, E K, John F. Sullivan, & G Frentz. (1985). Renal trauma: radiological studies. Comparison of urography, computed tomography, angiography, and radionuclide studies.. Radiology. 154(1). 1–6. 60 indexed citations

11.

Leslie, Bruce R., David B. Case, John F. Sullivan, & E D Vaughan. (1980). Absence of blood-pressure lowering effect of captopril in anephric patients.. BMJ. 280(6221). 1067–1068. 20 indexed citations

12.

Sullivan, John F.. (1970). AMPICILLIN IN THE TREATMENT OF GONORRHOEA IN GIRLS IN INSTITUTIONS. The Medical Journal of Australia. 2(17). 785–787. 1 indexed citations

13.

McHenry, Lawrence C., et al.. (1960). Mucocele of the Sphenoid Sinus. New England Journal of Medicine. 262(11). 549–551. 13 indexed citations

14.

Sullivan, John F., et al.. (1951). The electroencephalogram in cases of subdural hematoma and hydroma. Electroencephalography and Clinical Neurophysiology. 3(2). 131–139. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact